Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The adhesion and docking mechanism involving integrins, ICAM-1, and MFG-E8 on dendritic cells (DCs) and their exosomes (dexosomes) is a fundamental process for intercellular communication and immune regulation (Thery et al., 2002 [PMID: 12140582]). Dexosomes carry MHC-peptide complexes and adhesion molecules like ICAM-1 (CD54), which interact with integrins such as LFA-1 (CD11a/CD18) on the surface of DCs or T cells to facilitate antigen transfer and activation (Segura et al., 2005 [PMID: 15905584]). Additionally, Milk Fat Globule-EGF Factor 8 (MFG-E8), also known as lactadherin, acts as a molecular bridge by binding to phosphatidylserine on the exosome surface and to alpha-v beta-3 or alpha-v beta-5 integrins on the DC surface (Hanayama et al., 2002 [PMID: 11907578]). This multi-protein interaction ensures the efficient docking and internalization of exosomes, which is critical for the amplification of immune responses in cancer and infectious diseases. While the entire process is not a single therapeutic target, individual components like ICAM-1 and specific integrins are targeted by drugs such as Lifitegrast and Natalizumab to modulate inflammation and immune cell trafficking (Nolte-'t Hoen & Wauben, 2012 [PMID: 23071587]). Understanding this docking mechanism is vital for optimizing exosome-based drug delivery and immunotherapy.
Inhibition of leukocyte adhesion and exosome-mediated antigen transfer by blocking integrin-ligand interactions
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Adhesion and docking via integrins, ICAM-1, and MFG-E8 on dendritic cells and their exosomes.